Pays: États-Unis
Langue: anglais
Source: NLM (National Library of Medicine)
INSULIN GLARGINE (UNII: 2ZM8CX04RZ) (INSULIN GLARGINE - UNII:2ZM8CX04RZ)
A-S Medication Solutions
SUBCUTANEOUS
PRESCRIPTION DRUG
Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Limitations of Use Insulin glargine is not recommended for the treatment of diabetic ketoacidosis. Insulin glargine is contraindicated: - during episodes of hypoglycemia [see Warnings and Precautions (5.3)] - in patients with hypersensitivity to Insulin glargine or one of its excipients [see Warnings and Precautions (5.5)] Risk Summary Published studies with use of insulin glargine during pregnancy have not reported a clear association with insulin glargine and adverse developmental outcomes [see Data] . There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations] . Rats and rabbits were exposed to insulin glargine in animal reproduction studies during organogenesis, respectively 50 times and 10 times the human subcutaneous dose of 0.2 units/kg/day. Overall, the effects of insulin g
Product: 50090-6178 NDC: 50090-6178-0 3 mL in a SYRINGE / 5 in a CARTON
Biologic Licensing Application
INSULIN GLARGINE SOLOSTAR- INSULIN GLARGINE INJECTION, SOLUTION A-S MEDICATION SOLUTIONS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE INSULIN GLARGINE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR INSULIN GLARGINE. INSULIN GLARGINE INJECTION, FOR SUBCUTANEOUS INJECTION INITIAL U.S. APPROVAL: 2000 INDICATIONS AND USAGE Insulin glargine is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. (1) Limitations of Use Not recommended for treating diabetic ketoacidosis. (1) DOSAGE AND ADMINISTRATION Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. (2.1, 2.3, 2.4) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. (2.1) Do not dilute or mix with any other insulin or solution. (2.1) Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis. (2.2) Closely monitor glucose when changing to Insulin glargine and during initial weeks thereafter. (2.4) DOSAGE FORMS AND STRENGTHS Injection: 100 units/mL (U-100) available as: 10 mL multiple-dose vial (3) 3 mL single-patient-use SoloStar prefilled pen (3) CONTRAINDICATIONS During episodes of hypoglycemia (4) Hypersensitivity to Insulin glargine or one of its excipients (4) WARNINGS AND PRECAUTIONS _Never share_ an Insulin glargine SoloStar prefilled pen between patients, even if the needle is changed. (5.1) _Hyperglycemia or hypoglycemia with changes in insulin regimen_: Make changes to a patient's insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. (5.2) _Hypoglycemia_: May be life-threatening. Increase frequency of glucose monitoring with ch Lire le document complet